VMP Regimen - Safety Efficacy and Optimal Dose Finding Study for Patients With Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    Jan 31, 2023
  • participants needed
    203
  • sponsor
    Boryung Pharmaceutical Co., Ltd
Updated on 28 January 2021
melphalan
bortezomib

Summary

The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-nave patients with multiple myeloma who are ineligible for hematopoietic transplantation. Despite the fact that VMP therapy is outstanding in terms of cost-effectiveness, treatment discontinuation rates due to adverse drug reactions is high. In addition, when considering that the percentage of elderly patients aged 70 years or above in the target patient group is 20% or above, there have been attempts to devise a plan that can decrease side effects while maintaining effectiveness. For example, there have been previous reported cases of overseas applications of modified VMP therapies with reduced doses, but they have applied various combinations in terms of the total cycles, administration intervals, doses, etc. This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies.

This study was planned to evaluate the overall safety and efficacy of VMP therapy by following up on the actual VMP therapies applied in domestic clinics, patient characteristics, side effect occurrences, administration discontinuation rates, survival data, etc., as well as to collect exploratory data for a more effective study of modified VMP therapies.

Description

The data produced when subjects visit the hospital for treatment are collected in case report forms. The follow-up time specified in the following refer to the data collection time. That is, a subject's visit schedule is freely determined by the investigator based on the medical condition of the subject regardless of the follow-up time specified in this protocol, but data that are determined necessary in relation to the study among the data produced during the study period may be collected in CRFs.

In regard to various tests for monitoring of treatment effects including laboratory tests, the corresponding tests are not performed separately for this clinical study, and only those items with existing test results are collected. The following data are collected in CRFs during the study period.

  • Demographic information of subjects
  • Information on multiple myeloma disease (diagnosis date, diagnosis criteria and related test results, disease stage [ISS and revised ISS], number of osseous lesions)
  • Intercurrent diseases
  • Height and body weight
  • ECOG PS
  • IMWG Frailty score
  • Laboratory results
  • Radiologic results
  • Bone marrow examination results
  • Supportive therapy administered for symptoms related to multiple myeloma (drug / surgery / radiotherapy)
  • Detailed information of administered VMP therapy
  • Maintenance therapy / VMP replacement therapy
  • Clinical response
  • Survival
  • Adverse drug reactions related to VMP therapy
  • Serious adverse events/adverse drug reactions

Details
Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic Transplantation, multiple myeloma (mm)
Clinical Study IdentifierNCT04151615
SponsorBoryung Pharmaceutical Co., Ltd
Last Modified on28 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 19 yrs?
Gender: Male or Female
Do you have any of these conditions: Lymphoproliferative disorders or Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic Transplantation or Lymphoprolifer...?
Do you have any of these conditions: Lymphoproliferative disorders or Lymphoproliferative Disorder or Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic T...?
Do you have any of these conditions: Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic Transplantation or Multiple Myeloma or Lymphoproliferative disorde...?
Do you have any of these conditions: Treatment-naïve Patients With Multiple Myeloma Who Are Ineligible for Hematopoietic Transplantation or Lymphoproliferative disorders or Multiple Myelo...?
Patients who provide written consent on the informed consent form for use of personal information after listening to an explanation regarding the purpose, method, etc., of this clinical study
Adult males and females aged 19 years or above
Patients without previous experience of treatment for multiple myeloma who have been evaluated as ineligible for hematopoietic transplantation
Patients scheduled to receive the 3-drug combination (VMP therapy) treatment
Patients with expected survival period of 6 months or more
Patients evaluated as having performance status score (ECOG PS) 2 (score of 0, 1, 2)
Patients who have received the following tests within 6 months prior to enrollment
Beta2-microglobulin
Serum albumin
Serum LDH
Patients with confirmed del (17), t (4;14), t (14;16) by hybridization FISH test

Exclusion Criteria

Patients who have been newly diagnosed with other primary cancers within the last 5 years that can affect the treatment or prognosis of multiple myeloma
Pregnant women and breast-feeding women
Patients who are currently participating in other clinical studies (drug or medical device clinical studies) or planning to participate in other clinical studies during the study participation period
Patients who are determined ineligible to participate in the study by other judgments of the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note